



Deruxtecan [KLH] (DAG-WT672K)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	Deruxtecan conjugated with KLH
Conjugate	KLH
Cas.No	1599440-13-7
Applications	N/A
Format	Liquid
Concentration	Batch dependent - please inquire should you have specific requirements
Size	1 mg
Buffer	PBS buffer
Preservative	None
Storage	Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles

BACKGROUND

Introduction	Deruxtecan, a topoisomerase I inhibitor, is an exatecan derivative (DX-8951 derivative) with a cleavable peptide linker and a maleimide group. The maleimide group in Deruxtecan can react with antibody to form antibody-drug conjugates (ADC) such as Trastuzumab deruxtecan (DS-8201a), which is a HER2-targeting antibody–drug conjugate. DS-8201a significantly suppressed tumor growth in an immunocompetent mouse model with human HER2-expressing CT26.WT (CT26.WThER2) cells. DS-8201a is currently in clinical trials
Keywords	Deruxtecan; Trastuzumab deruxtecan; Glycinamide